Personalized medicine in gastric cancer: Where are we and where are we going? - Wikidata - wikimedia - TriplyDB

Personalized medicine in gastric cancer: Where are we and where are we going?

Personalized medicine in gastric cancer: Where are we and where are we going?

http://www.wikidata.org/entity/Q26774521

about

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway.Gastric Cancer Genomics: Advances and Future Directions.Gastric cancer management: Kinases as a target therapy.Comparative efficacy and safety of Chinese herbal injections combined with the FOLFOX regimen for treating gastric cancer in China: a network meta-analysis.Validation of the 8th AJCC staging system for gastric cancer in a population-based setting.PCDHGA9 acts as a tumor suppressor to induce tumor cell apoptosis and autophagy and inhibit the EMT process in human gastric cancer.PTEN gene silencing contributes to airway remodeling and induces airway smooth muscle cell proliferation in mice with allergic asthma.(S)-crizotinib reduces gastric cancer growth through oxidative DNA damage and triggers pro-survival akt signal.

P2860

Q28078111-E746EE1B-8CA5-4B66-BFBE-7EDFDACD4890 Q33779412-F47493AE-91F6-43D9-AF3A-AFEE4542EA64 Q37602508-F9959796-824B-49BF-A2C8-0AC55685D0F2 Q37673604-303E7B06-397E-48DD-BD19-05D587440C43 Q38749038-DCD127ED-D6B5-4835-BE9C-DF24DC27D4FA Q42060519-7FD44219-7024-4AC9-BDAE-69B8D03F469C Q48189935-828D97D1-6CBD-4296-85AA-D66A108FA7C8 Q49950482-CEDD3EE6-FD48-4BB5-972E-D4F37C17A8A8 Q52337419-69B99327-F7D0-486D-824F-693C03CA3968 Q54977436-7C76634E-7D7D-4739-AD51-D9D7B9078EDE

P2860

Personalized medicine in gastric cancer: Where are we and where are we going?

http://www.wikidata.org/entity/Q26774521

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Personalized medicine in gastric cancer: Where are we and where are we going?

@ast

Personalized medicine in gastric cancer: Where are we and where are we going?

@en

Personalized medicine in gastric cancer: Where are we and where are we going?

@nl

type

label

Personalized medicine in gastric cancer: Where are we and where are we going?

@ast

Personalized medicine in gastric cancer: Where are we and where are we going?

@en

Personalized medicine in gastric cancer: Where are we and where are we going?

@nl

prefLabel

Personalized medicine in gastric cancer: Where are we and where are we going?

@ast

Personalized medicine in gastric cancer: Where are we and where are we going?

@en

Personalized medicine in gastric cancer: Where are we and where are we going?

@nl

P1433

Q26774521-340A0B5C-E350-4DC9-9B16-0C578A7766AE

P1476

Q26774521-9F23E8DF-A229-42F6-BA60-9F7319D08B42

P2093

Q26774521-1CB56276-FD35-48C1-B18A-DE70BC33DD2A

Q26774521-676CFC55-1AAD-4273-8BAD-734CE9FB1D9D

Q26774521-6B7DCDD6-10BE-46A9-876B-C472DF32A773

Q26774521-C7DE24E7-3FDB-45E3-B59B-1D5BFC67E2C8

P2860

Q26774521-02BE4624-D501-49C7-8931-EC06523405AB

Q26774521-04469515-80C0-409E-8FB2-FB3828335C99

Q26774521-0726C0A9-73BB-4701-A29E-5ECCC89929BE

Q26774521-07E18DEB-53A5-442F-9639-4A6233A5A9E6

Q26774521-0AD63F15-8128-4272-90D3-6AF953AB6F65

Q26774521-1B41F2C1-C4D5-4FFF-8424-4FFE64381600

Q26774521-1C3B777E-C1BD-40D1-97B1-FD7DB59E74B0

Q26774521-20B81395-C6B5-413C-BABB-A9C66E20960B

Q26774521-26418C94-D911-425C-90F9-5850E4B4A87E

Q26774521-2C6E81DC-A742-4F4A-96F9-B735C6597051

P304

Q26774521-1B072A32-D970-4E4A-969E-3BF5DCF1A562

P31

Q26774521-8539EEBD-98A4-497E-9CBE-303D0DB4A9C0

P3181

Q26774521-04B78E66-7681-4841-9978-D9888EA5E71F

P356

Q26774521-AAFAEF03-8BC3-4D11-B339-1D6E31AF0D68

P407

Q26774521-6EC6FB6D-69DE-482C-9297-ED6EBE3FB197

P433

Q26774521-C2AB1840-4A10-4989-BCBA-012EDFC1710A

P478

Q26774521-B043C32A-536E-429F-A5B8-48A9AD6DA953

P50

Q26774521-38E1E5E2-E897-4BCF-B237-D2A9497D4FBD

P577

Q26774521-D3F6F40A-1936-4F80-9242-D1BA64E19240

P5875

Q26774521-C6316EAD-8D75-4DB8-9F7C-7B543F0F6F6C

P698

Q26774521-D1598125-BFD1-4474-BF6D-F06252216803

P932

Q26774521-295122B3-48C3-4D3C-95F5-EE66711BE7F0

P3181

P356

WJG.V22.I3.1160

P1433

World Journal of Gastroenterology

P1476

Personalized medicine in gastric cancer: Where are we and where are we going?

@en

P2093

Alexandre A Jácome

http://www.w3.org/2001/XMLSchema#string

Aline C Andrade

http://www.w3.org/2001/XMLSchema#string

Anelisa K Coutinho

http://www.w3.org/2001/XMLSchema#string

Enaldo M Lima

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of PIK3CA in gastric adenocarcinoma

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Global cancer statistics, 2012

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

The blockade of immune checkpoints in cancer immunotherapy

P304

1160-1171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3734764

http://www.w3.org/2001/XMLSchema#string

P356

10.3748/WJG.V22.I3.1160

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

José Sebastião dos Santos

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290625463

http://www.w3.org/2001/XMLSchema#string

P698

26811654

http://www.w3.org/2001/XMLSchema#string

P932

4716027

http://www.w3.org/2001/XMLSchema#string